Work

Phase I Study of FT516, an Off-the-Shelf iPSC-Derived NK Cell Therapy, in Combination with Rituximab in Patients with Relapsed/Refractory B-Cell Lymphoma

Year: 2021

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2021-151520

Authors: Krish Patel, Veronika Bachanova, Aaron M Goodman, John M. Pagel, Kelly Griffis, Marlisa Anderson, Siminder Atwal, Cara Bickers, Peter Szabo, Lilly Wong, Yu-Waye Chu, Rebecca Elstrom, Paolo Strati

Institutions: University of Minnesota, Masonic Cancer Center, University of California San Diego, Moores Cancer Center, Fate Therapeutics (United States), The University of Texas MD Anderson Cancer Center

Language: English

Topic: Immune Cell Function and Interaction

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3213739826

Cites:

Cited by: 20

Related to: 10